Clinical Trials to Improve Outcomes in Patients with Elevated Lp(a) Undergoing PCI: The Time Has Arrived
Lipoprotein(a) [Lp(a)] is a highly prevalent, genetic, and independent risk factor for cardiovascular disease (CVD) and aortic stenosis. The underlying mechanisms of increased risk include pro-inflammatory effects of its associated oxidized phospholipids (OxPL), pro-atherogenic effects of the LDL-like moiety and antifibrinolytic effects of the inactive protease-like domain on Kringle V of apolipoprotein(a).1 Although elevated Lp(a) is associated with increased risk of CVD in both primary and secondary prevention settings, an understudied area of Lp(a) biology is its role in outcomes following percutaneous coronary intervention (PCI).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Sotirios Tsimikas, Harpreet S. Bhatia, David Erlinge Tags: Editorial Source Type: research
More News: Angioplasty | Aortic Stenosis | Biology | Cardiology | Cardiovascular | Clinical Trials | Coronary Angioplasty | Genetics | Heart | Lipidology | Percutaneous Coronary Intervention